{"id":"ibi306","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Decreased appetite"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Infusion-related reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IBI306 is a humanized monoclonal antibody targeting programmed death receptor 1 (PD-1). By blocking PD-1, the drug prevents tumor cells from suppressing T cell-mediated immunity, allowing the immune system to recognize and attack cancer cells more effectively. This mechanism is similar to other checkpoint inhibitors in clinical use.","oneSentence":"IBI306 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:11.016Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Gastric cancer"},{"name":"Esophageal cancer"}]},"trialDetails":[{"nctId":"NCT07473960","phase":"PHASE3","title":"IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia","status":"NOT_YET_RECRUITING","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2026-04-01","conditions":"Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia","enrollment":198},{"nctId":"NCT04709536","phase":"PHASE3","title":"A Study of IBI306 in Participants With Hypercholesterolemia","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2021-02-09","conditions":"Hypercholesterolemia","enrollment":306},{"nctId":"NCT03815812","phase":"PHASE2","title":"Multiple Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Chinese Patients With Hypercholesterolemia","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-03-07","conditions":"Hypercholesterolemia","enrollment":60},{"nctId":"NCT05792917","phase":"PHASE1","title":"Bioequivalence Study of Tafolecimab Injections in Chinese Healthy Male Volunteers","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2023-03-06","conditions":"Healthy Male Subjects","enrollment":166},{"nctId":"NCT04179669","phase":"PHASE3","title":"Safety and Efficacy of IBI306 in HeFH Patients","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-12-20","conditions":"Heterozygous Familial Hypercholesterolemia","enrollment":149},{"nctId":"NCT04031742","phase":"PHASE2, PHASE3","title":"A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-09-29","conditions":"Homozygous Familial Hypercholesterolemia","enrollment":18},{"nctId":"NCT04289285","phase":"PHASE3","title":"Safety and Efficacy of IBI306 in Chinese Subjects With Non-familial Hypercholesterolemia","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2020-04-29","conditions":"Hypercholesterolemia","enrollment":804},{"nctId":"NCT04759534","phase":"PHASE3","title":"Application of PCSK9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2020-09-10","conditions":"Efficacy and Safety, Heterozygous Familial Hypercholesterolemia, PCSK9","enrollment":20},{"nctId":"NCT04948008","phase":"PHASE2, PHASE3","title":"Evaluate the Efficacy and Safety of IBI306 in Subjects With Homozygous Familial Hypercholesterolemia","status":"UNKNOWN","sponsor":"Shenzhen People's Hospital","startDate":"2019-11-05","conditions":"Familial Hypercholesterolemia - Homozygous, Lipid Metabolism Disorders, Proprotein Convertase Subtilisin/Kexin 9","enrollment":8},{"nctId":"NCT03366688","phase":"PHASE1","title":"Single Ascending Dose Study of PCSK-9 Inhibitor (IBI306) in Healthy Subjects.","status":"COMPLETED","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2017-11-27","conditions":"Hypercholesterolemia","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"IBI306","genericName":"IBI306","companyName":"Innovent Biologics (Suzhou) Co. Ltd.","companyId":"innovent-biologics-suzhou-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IBI306 is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Non-small cell lung cancer, Gastric cancer, Esophageal cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":6,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}